for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Advaxis Announces Updated Positive Clinical Data In Ongoing Phase 1/2 ADXS-503 Trial In NSCLC

Feb 27 (Reuters) - Advaxis Inc:

* ADVAXIS ANNOUNCES UPDATED POSITIVE CLINICAL DATA IN ONGOING PHASE 1/2 ADXS-503 TRIAL IN NSCLC AT I/O 360° CONFERENCE

* ADVAXIS INC - KEYTRUDA SHOWED SUBSTANTIAL TUMOR SHRINKAGE WITH ADXS-503 TREATMENT IN COMBINATION WITH KEYTRUDA

* ADVAXIS INC - PARTIAL RESPONSE OBSERVED IN ONE PATIENT AND OTHER PATIENT ACHIEVED STABLE DISEASE WITH A 25% REDUCTION IN A TARGET LESION Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up